Sharemaestro company-news research for Krystal Biotech Inc (KRYS), showing current tone, evidence confidence, direct company coverage, sector and industry context, completed price response and the source headlines used on the page. Scores describe published news evidence. Confidence describes the amount, freshness, source breadth and direct company relevance of that evidence. Price context is shown separately.
NASDAQ
United States
Measured evidence
Company news sentiment
KRYS news sentiment
Krystal Biotech Inc
Company headlines compared by relevance, subject, source independence, tone and the market's completed price response.
Weighted tone57Neutral is 50
Balanced news tone
50/100 evidence confidence
100% direct company focus
2 current stories across 2 publishers
Current company news
Price moving ahead of tone
Balanced news tone is drawn from 2 fresh independent stories, including 2 company-specific items across 2 publishers.
Latest source headline Krystal Biotech (KRYS) Stock May Be Fully Valued After Its 5x Run finance.yahoo.com · 10 Aug 2026 08:12What supports the read
2 current stories are mapped specifically to KRYS.
Cross-story agreement is 74/100, indicating a comparatively coherent tape.
What tempers the read
Only 2 publishers currently contribute to the measured read.
Price is moving more forcefully than the current news tone suggests.
57/100
Weighted toneBalanced news tone
50/100
Evidence confidencebuilding confidence
100%/100
Company focus2 direct stories
74/100
Evidence agreement26/100 dispersion
News history
Tone and story flow over 21 days
24 Jul03 Aug13 Aug
Weighted toneStory volumeNeutral 50
Evidence confidence
What supports the score
Confidence rises through sample depth, independent publishers, direct company relevance, freshness and agreement. A high or low tone score is not itself evidence of reliability.
Sample depth24
1.94 effective storiesSource breadth40
2 independent publishersDirect relevance100
company-specific evidence shareFreshness52
recency-weighted evidenceAgreement74
cross-story consistencySource independence48
lower publisher concentrationPrice context
Sentiment against the 26-week price path
Price is moving more forcefully than the current news tone suggests.
13 Feb15 May07 Aug
Weekly close, indexedSentiment score
News subjects
What is shaping the score
Earnings871 stories · 50%
Deals and strategy341 stories · 50%
Source mix
Where the evidence comes from
finance.yahoo.com871 stories · 50%
seekingalpha.com341 stories · 50%
Recurring subjects
Subjects appearing most often
Biotech2Valuation1Share Price1Revenue Growth1Pharma1Oncology1M&a1M A1Fda Approval1Earnings Report1
Earlier readings
How the score has changed
ConstructiveBalanced or withheldCautious
Source headlines
The news behind the score
Every row shows the public evidence used to understand the read. Direct company stories carry more weight than industry or sector context; duplicate coverage is consolidated before scoring.
#187Tone
finance.yahoo.comDirect company coverage
Krystal Biotech (KRYS) Stock May Be Fully Valued After Its 5x Run
Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. Krystal Biotech stock has delivered a very large 5 year return while recent valuation checks and the latest share price action suggest the current market price may already be baking in high expectations. Krystal Biotech has returned roughly 5x over the past 5 years, which puts extra focus on whether the current share price still offers an appealing entry point or mainly reflects past success. Ongoing adoption of its genetic medicine platform can support the current valuation,
BiotechEarningsEarnings ReportRevenue GrowthShare PriceValuation
- Published
- 10 Aug 2026 08:12
- Catalyst
- Earnings
- Evidence role
- Direct company coverage
- Duplicates
- 1 consolidated
#234Tone
seekingalpha.comDirect company coverage
SA Asks: What's the outlook for Big Pharma M&A?
[Medical research with pipette and test tube, DNA analysis, biotechnology, genetic science and healthcare] jittawit.21 Big Pharma moved back into the spotlight last week following a Financial Times report that Bristol Myers Squibb (BMY [https://seekingalpha.com/symbol/BMY]) was in merger talks with AstraZeneca (AZN [https://seekingalpha.com/symbol/AZN]), a development that was later denied by unnamed sources to Reuters. We asked Seeking Alpha analysts Stephen Ayers [https://seekingalpha.com/author/stephen-ayers], ALLKA Research [https://seekingalpha.com/author/allka-research], and Chris DeMuth
BiotechFda ApprovalM&aM AOncologyPharma
- Published
- 08 Aug 2026 19:28
- Catalyst
- Deals and strategy
- Evidence role
- Direct company coverage
- Duplicates
- 1 consolidated
Earlier company news
KRYS news archive
Stored newest first for historical research. These older headlines are retained for reference and do not contribute to the current sentiment gauge above.
Aug
08
2026
simplywall.stArchivedNeutral tone
Krystal Biotech (KRYS) After Its Q2 Beat Is The Valuation Case Still Intact
- Published
- 8 Aug 2026 06:17
- Catalyst
- Historical snapshot
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Aug
02
2026
simplywall.stArchivedPositive tone
Does KB801’s Single-Patient Signal And S&P 400 Move Change The Bull Case For Krystal Biotech (KRYS)?
- Published
- 2 Aug 2026 01:35
- Catalyst
- Historical snapshot
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Aug
01
2026
Quiver QuantitativeArchivedPositive tone
Krystal Biotech slides as investors appear to reset ahead of earnings
- Published
- 1 Aug 2026 03:26
- Catalyst
- Historical snapshot
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Jul
28
2026
TradingKeyArchivedPositive tone
Krystal Biotech Inc (KRYS) Valuation: PE, PB & Fair Value Analysis
- Published
- 28 Jul 2026 19:36
- Catalyst
- Historical snapshot
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Jul
28
2026
TradingKeyArchivedPositive tone
Krystal Biotech Inc (KRYS) Institutional Confidence
- Published
- 28 Jul 2026 19:16
- Catalyst
- Historical snapshot
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Jul
25
2026
Yahoo! Finance CanadaArchivedPositive tone
Krystal Biotech, Inc. (KRYS) Stock Price, News, Quote & History
- Published
- 25 Jul 2026 00:30
- Catalyst
- Historical snapshot
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Jul
23
2026
Seeking AlphaArchivedPositive tone
Biotech stocks lead healthcare's overbought list as earnings picks up (XLV:NYSEARCA)
- Published
- 23 Jul 2026 14:35
- Catalyst
- Historical snapshot
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Jul
23
2026
simplywall.stArchivedPositive tone
Is A Single-Patient KB801 Outcome Quietly Reframing Krystal Biotech's Clinical Narrative (KRYS)?
- Published
- 23 Jul 2026 11:51
- Catalyst
- Historical snapshot
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Jul
22
2026
Simply Wall StreetArchivedPositive tone
Is Krystal Biotech (KRYS) Overvalued On Its KB801 Patent Data Update?
- Published
- 22 Jul 2026 17:39
- Catalyst
- Historical snapshot
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Jul
21
2026
GuruFocusArchivedPositive tone
Krystal Biotech (KRYS) Joins S&P MidCap 400 Amid Index Changes
- Published
- 21 Jul 2026 20:03
- Catalyst
- Historical snapshot
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Jul
19
2026
StocksToTradeArchivedPositive tone
KRYS Jumps As Analysts Race To Lift Price Targets
- Published
- 19 Jul 2026 18:37
- Catalyst
- Historical snapshot
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Jul
18
2026
Quiver QuantitativeArchivedPositive tone
Krystal Biotech Rises as Investors Lean on Commercial Momentum and Pipeline Catalysts
- Published
- 18 Jul 2026 14:57
- Catalyst
- Historical snapshot
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Jul
15
2026
Simply Wall StreetArchivedPositive tone
Is Krystal Biotech (KRYS) Too Expensive After A 440% Return?
- Published
- 15 Jul 2026 17:48
- Catalyst
- Historical snapshot
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Jul
12
2026
Stock Traders DailyArchivedPositive tone
(KRYS) and the Role of Price-Sensitive Allocations
- Published
- 12 Jul 2026 06:37
- Catalyst
- Historical snapshot
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Jul
06
2026
TradingViewArchivedPositive tone
Price to book forward of Krystal Biotech, Inc. – NASDAQ:KRYS
- Published
- 6 Jul 2026 18:44
- Catalyst
- Historical snapshot
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Jul
04
2026
FinvizArchivedPositive tone
KRYS - Krystal Biotech Inc Options
- Published
- 4 Jul 2026 21:09
- Catalyst
- Historical snapshot
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Jul
03
2026
Simply Wall StreetArchivedPositive tone
FDA PreCheck Could Speed Up These 3 U.S. Biopharma Stocks
- Published
- 3 Jul 2026 02:55
- Catalyst
- Historical snapshot
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Jul
02
2026
MSNArchivedPositive tone
Krystal Biotech stock soars 16% in three months: Here's why
- Published
- 2 Jul 2026 19:44
- Catalyst
- Historical snapshot
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Jun
29
2026
Investing.com South AfricaArchivedPositive tone
Form 4 Krystal Biotech Inc For: 26 June By Investing.com
- Published
- 29 Jun 2026 14:07
- Catalyst
- Historical snapshot
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Jun
28
2026
Stock Traders DailyArchivedPositive tone
Responsive Playbooks and the KRYS Inflection
- Published
- 28 Jun 2026 10:06
- Catalyst
- Historical snapshot
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Jun
27
2026
Investing.com CanadaArchivedPositive tone
Krystal Biotech EVP sells $347,270 in common stock By Investing.com
- Published
- 27 Jun 2026 21:45
- Catalyst
- Historical snapshot
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Jun
26
2026
Simply Wall StreetArchivedPositive tone
Krystal Biotech (KRYS) Rallies On Pipeline Optimism, Is The Stock Already Pricey?
- Published
- 26 Jun 2026 19:52
- Catalyst
- Historical snapshot
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Jun
25
2026
TradingViewArchivedPositive tone
Enterprise value to revenue forward of Krystal Biotech, Inc. – NASDAQ:KRYS
- Published
- 25 Jun 2026 14:04
- Catalyst
- Historical snapshot
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Jun
25
2026
TradingViewArchivedPositive tone
Price to sales forward of Krystal Biotech, Inc. – NASDAQ:KRYS
- Published
- 25 Jun 2026 12:35
- Catalyst
- Historical snapshot
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Jun
24
2026
Market sourceArchivedPositive tone
The Brown Capital Management Small Company Fund Bets on Krystal Biotech (KRYS) for Its Resilient Revenue Stream
- Published
- 24 Jun 2026 21:11
- Catalyst
- Historical snapshot
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Jun
24
2026
Ad-hoc-news.deArchivedPositive tone
Krystal Biotech updates key Vyjuvek filing, shares trade firmly on Nasdaq
- Published
- 24 Jun 2026 08:53
- Catalyst
- Historical snapshot
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Jun
23
2026
Simply Wall StreetArchivedPositive tone
Krystal Biotech (KRYS) Is Up 7.2% After Institutional Ownership Surges To Sector-Leading Levels
- Published
- 23 Jun 2026 10:22
- Catalyst
- Historical snapshot
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Jun
22
2026
MarketBeatArchivedPositive tone
3 Biotech Firms With Major Potential Catalysts in the Coming Months
- Published
- 22 Jun 2026 16:07
- Catalyst
- Historical snapshot
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Jun
21
2026
Simply Wall StreetArchivedPositive tone
3 US Pharmaceutical Stocks With Strong Margins And Earnings Growth
- Published
- 21 Jun 2026 03:41
- Catalyst
- Historical snapshot
- Coverage
- Direct company
- Duplicates
- 1 consolidated
How the page works
How to read the score
It describes the weighted balance of qualifying headlines. A score of 50 can mean a balanced tape or that direction has been withheld for insufficient evidence; the status label distinguishes them.
Confidence measures depth, source breadth, direct relevance, freshness and agreement. It does not rise merely because the tone is extreme.
Weekly price response, trend and fair-value position test whether the market is accepting or rejecting the news. They never rewrite the news score.
The page describes completed evidence available at the stated time. It is research context, not a forecast, recommendation, target or execution instruction.